I
Ikena Oncology
Biotech & Life Sciences · Boston, United States · Founded 2016 · IPO 2021
Patient-directed oncology therapies across pathways relevant in tumor and immune cells MoreLess
Ikena Oncology is a biotechnology company focused on developing targeted therapies for cancer patients. The company operates in the oncology market, aiming to address the unmet needs of patients by targeting specific nodes of cancer growth, spread, and therapeutic resistance. Ikena's business model revolves around the research and development of differentiated oncology therapies, leveraging a deep institutional knowledge and a broad array of tools to create the right drug for the right patient. The company generates revenue through partnerships, licensing agreements, and the eventual commercialization of its therapies. Ikena serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, all focused on improving cancer treatment outcomes.
Keywords: targeted oncology, cancer therapies, drug development, biotechnology, cancer growth, therapeutic resistance, healthcare providers, research institutions, pharmaceutical partnerships, commercialization.
Company overview
Ikena Oncology company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Boston, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 28.6
- Investment activity
- 1 companies · latest Aug 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Ikena Oncology funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Dec 2024 | $75M | — | Foresite Capital · Deep Track Capital · Blue Owl Capital · OrbiMed | ↗ |
| ACQUISITIONOther financing | Dec 2024 | $0 | — | Inmagene Biopharmaceuticals | ↗ |
| POST IPO EQUITYOther financing | May 2023 | $40M | — | Undisclosed | ↗ |
| IPOOther financing | Apr 2021 | $144M | $480M | Undisclosed | — |
| SERIES BOther financing | Jan 2021 | $120M | $480M | Atlas Venture · Fidelity Investments · Cowen Group · Invus | — |
| EARLY VCOther financing | Jan 2019 | Bristol-Myers Squibb · Celgene | — | ||
| SERIES AOther financing | Dec 2017 | Atlas Venture · OrbiMed | — | ||
| SPINOUTOther financing | Jan 2016 | University of Texas at Austin | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$57M | — |
| 2025 | $0 | — | −$57M | — |
| 2024 | $0 | -100% | −$57M | — |
| 2023 | $9.2M | -41.3% | −$82M | -889.8% |
| 2022 | $16M | -49.6% | −$70M | -449.2% |
| 2021 | $31M | +237% | −$34M | -108.4% |
| 2020 | $9.2M | — | −$44M | -481% |
Growth signals
Ikena Oncology website traffic
Latest recorded traffic for Ikena Oncology is 290 monthly website visits, down 90.9% over the last three months. Ikena Oncology's team declined 31.6% over the past year.
Comparisons
Ikena Oncology compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Ikena Oncology investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Ikena Oncology's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Ikena Oncology has talent and traffic
team presence
In the news
Latest news about Ikena Oncology
Recent press, funding announcements, and product moves mentioning Ikena Oncology — open to read from the original sources.
Market sentiment
What the market is saying about Ikena Oncology
An AI-synthesized read of the highest-engagement posts about Ikena Oncology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ikena Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.